Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated written informed consent.~* Male or female patients diagnosed with type 1 diabetes (T1D) at least 6 months prior to informed consent or type 2 diabetes (T2D) or non-diabetic obese patients.~* T1D patients must use and be willing of and be willing to continue throughout the duration of the trial either:~* multiple daily injections of insulin OR~* continuous sub-cutaneous insulin infusion of any insulin type, with at least 3 months experience~* For patients with T1D or T2D,HbA1c of 6.5 - 11%~* Age at least 18 years of age~* Body mass index of \>=18.5 kg/m\^2~* Estimated glomerular filtration rate greater than or equal to 60 ml/min/1.73m2~* Blood pressure greater than 90 /60 mmHg and less than or equal to 140 / 90 mmHg~* Use of a highly effective method of contraception.~* Further inclusion criteria apply~Exclusion criteria:~* For patients with T1D, treatment with an antihyperglycaemic agent within 3 months prior to visit 1~* occurrence of severe hypoglycaemia within 3 months prior to visit 1~* hypoglycaemic unawareness within 3 months prior to visit 1~* occurrence of diabetic ketoacidosis within 3 months of visit 1 and until visit 3 Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: EXPERIMENTAL): Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
- Sequence B (Type: EXPERIMENTAL): Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.

Based on this trial design, predict the completion outcome and termination type (if applicable).